-
American Psychiatric Association (APA). Handboek voor de classificatie van psychische stoornissen (DSM-5). 2014.
-
Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Multidisciplinaire Richtlijn ADHD. Richtlijn voor de diagnostiek en behandeling van ADHD bij kinderen en jeugdigen. Utrecht: Trimbos-instituut. 2005.
-
Kooij J. ADHD bij volwassenen. Ned Tijdschr Geneeskd. 2017;161:D1660, D2102.
-
Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345-65.
-
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychological medicine. 2006;36(2):159–65.
-
Tuithof M, Ten Have M, Van Dorsselaer S, et al. Prevalentie, persistentie en gevolgen van ADHD in de Nederlandse volwassen bevolking. Tijdsch Psych. 2014;56(1):10-19.
-
Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-56.
-
Kooij JJ, Buitelaar JK, van den Oord EJ, et al. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005;35(6):817-27.
-
Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204-11.
-
Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-9.
-
Michielsen M, Semeijn E, Comijs HC, et al. Prevalence of attention deficit hyperactivity disorder in older adults in The Netherlands. Br J Psychiatry. 2012;201:298-305.
-
Solberg BS, Halmøy A, Engeland A, Igland J, et al. Gender differences in psychiatric comorbidity: a population‐based study of 40 000 adults with attention deficit hyperactivity disorder. Acta Psychiat Scand. 2018;137(3):176–86.
-
Rucklidge JJ. Gender differences in ADHD: implications for psychosocial treatments. Expert Rev Neurother. 2014;8(4):643–55.
-
Mowlem FD, Rosenqvist MA, Martin J, et al. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adoles Psy. 2019;28(4):481–89.
-
Fayyad J, Sampson NA, Hwang I, et al. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017;9:47-65.
-
Biederman J, Faraone SV, Monuteaux MC, et al. Gender effects on Attention-Deficit/Hyperactivity disorder in adults, revisited. Biol Psychiat. 2004;55(7):692–700.
-
Demontis D, Walters R, Neale B. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics. 2018; 51:63-75.
-
-
Dumont GJH. Praktische farmacotherapie bij ADHD. 2e editie. Amsterdam: Lannoo Campus; 2020
-
Rubia K, Alegría AA, Brinson H. Brain abnormalities in attention-deficit hyperactivity disorder: a review. Rev Neurol. 2014;58(Suppl 1):S3-16.
-
Daley D, Jacobsen RH, Sørensen A, et al. The economic burden of adult attention deficit hyperactivity disorder: a sibling comparison cost analysis. Eur Psychiatry. 2019;61:41-8.
-
Masuch TV, Bea M, Alm B, et al. Internalized stigma, anticipated discrimination and perceived public stigma in adults with ADHD. Atten Defic Hyperact Disord. 2019;11(2):211-20.
-
-
Cortese S, Asherson P, Sonuga-Barke E, et al.; European ADHD Guidelines Group. DHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. Lancet Child Adolesc Health. 2020;4(6):412-14.
-
Stijntjes F, Hassink-Franke L, Kruishoop A, et al. NHG-Standaard ADHD bij kinderen. Huisarts Wet 2014;57(11):584-94.
-
Nederlands Huisartsen Genootschap (NHG). Aandachtspunten bij patiënten ≥ 18 jaar die ADHD-middelen gebruiken. Bijlage bij het NHG-Standpunt Herhalen gespecialiseerde ggz-medicatie. https://richtlijnen.nhg.org/files/2020-12/Aandachtspunten bij patiënten ≥ 18 jaar die ADHD-middelen.pdf. Geraadpleegd juni 2021.
-
Cole E. Qb test improves diagnosis of attention deficit disorder. Nurs Child Young People. 2015;27(2):10-11.
-
-
Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3e editie. New York:Guilford Press. 2006.
-
Montoya A, Colom F, Ferrin M. Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review. Eur Psychiatry 2011; 26(3):166-175.
-
Kaldenbach Y. Therapietrouw bij kinderen en adolescenten met ADHD. ADHD Actueel, Academic Pharmaceuticals Production B.V. 2007;4(2).
-
Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS drugs. 2008;22(2):157-70.
-
Schawo S, van der Kolk A, Bouwmans C, et al. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed? PharmacoEconomics. 2015;33(5):489-509.
-
Van der Schans J, Kotsopoulos N, Hoekstra PJ, et al. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. PloS one. 2015;10(5):e0127237.
-
Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-95.
-
Van Gompel AHP. Methylfenidaat bevattende producten met gereguleerde afgifte niet onderling uitwisselbaar. GeBu 2007;4(41):47-8.
-
Döpfner M, Ose C, Fischer R, et al. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®) -a randomized, controlled, double-blind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol. 2011;21(5):445-54.
-
-
-
-
Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754-63.
-
-
-
Dolder PC, Strajhar P, Vizeli P, et al. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with d-Amphetamine in Healthy Subjects. Front. Pharmacol. 2017;8:617.
-
Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27.
-
Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009;23(4):410-18.
-
Chang Z, Lichtenstein P, D’Onofrio BM, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014;71(3):319-25.
-
Boland H, Disalvo M, Fried R, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psyciat Res. 2020;123:21-30.
-
Fernandez-Jaen A, Fernandez-Mayoralas DM, Calleja-Perez B, et al. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label. J Atten Disord. 2013;17(6):497-505.
-
-
-
-